Free Nursing CE

In this online, self-learning activity:

Osteoporosis in aging men is a growing public health problem yet remains under-recognized in primary and specialty care. Population-based cohorts show that adults aged ≥80 years now account for most hip fractures, and in this age group men experience higher perioperative morbidity and mortality than women at comparable ages. Contemporary US trend analyses confirm a high and in some groups increasing prevalence of osteoporosis and low bone mass among adults ≥50 years, with substantial burden among older men. Health-economic models and actuarial reports estimate more than two million osteoporotic fractures annually in the United States, costing about $17 billion in 2005 and rising to an estimated $57 billion over the past two decades, with further growth expected by 2040; men already account for more than one-quarter of this burden. Prospective outcomes work from the ICUROS US study and Medicare claims analyses underscores prolonged quality-of-life loss and markedly higher all-cause costs after fragility fractures, especially hip and vertebral fractures in older adults, including men.

Explore recent findings in Pain Reprocessing Therapy with Yoni K. Ashar, PhD. This free lecture connects emerging research with assessment, patient education, and treatment planning for chronic pain.

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Discover how communities of practice are expanding access to bispecific antibodies, as faculty share practical guidance on starting these therapies in community settings and smoothly transitioning patients from academic centers to local care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

In this online, self-learning activity:

Neonatal respiratory distress syndrome (nRDS) remains a leading cause of respiratory failure and morbidity among preterm infants worldwide, despite major advances in antenatal steroids, continuous positive airway pressure (CPAP), and surfactant therapy. Contemporary guidelines emphasize early noninvasive respiratory support from birth, selective surfactant rescue once CPAP begins to fail, and structured, protocolized care across gestational age strata. Yet practice-pattern studies across high- and middle-income settings show wide variation in initial respiratory support, surfactant thresholds, and use of minimally invasive techniques, with extremely preterm and late preterm infants often receiving care that diverges from guideline-concordant pathways. These inconsistencies increase cumulative ventilator exposure and risk of bronchopulmonary dysplasia (BPD) and other complications, underscoring a persistent implementation gap between best evidence and routine NICU care.

In this online, self-learning activity:

Asthma remains a highly prevalent chronic respiratory disease, affecting more than 26 million people in the United States, including over 4.5 million children, with several thousand deaths and substantial emergency department and inpatient utilization each year despite effective preventives. Persistent symptoms, recurrent exacerbations, and preventable hospitalizations indicate gaps in risk stratification and in the consistent application of guideline-based care, even with comprehensive frameworks such as the Global Initiative for Asthma (GINA) strategy. Many severe attacks still occur, requiring parenteral bronchodilators, systemic corticosteroids, magnesium sulfate, oxygen, and respiratory-support devices, underscoring missed opportunities to optimize maintenance regimens and device use upstream.

This webcast focuses on the role of wearable devices in the timely identification of atrial fibrillation (AF) and the evolving evidence around the rationale for and efficacy/safety of early rhythm control strategies, including guideline recommendations and expert insights on the use of antiarrhythmic drugs (AADs) and catheter ablation. It also incorporates an AI-powered patient simulator as a method by which participants can practice how they engage patients in shared decision-making discussions regarding rhythm control strategies

Hear from a panel of clinicians from community practices about their experiences, including the challenges and successes, with integrating B-cell maturation antigen (BCMA)-directed bispecific antibodies into their practices. Explore patient management strategies for bispecific antibodies, from starting treatment at a community center to providing long-term care after treatment initiation at either a community or tertiary center.

This CME activity reviews the efficacy and safety of available B-cell maturation antigen (BCMA)-directed bispecific antibodies for multiple myeloma and explores the latest clinical data on their use in earlier lines of therapy and in emerging combination regimens.

This CME activity reviews various barriers to accessing B-cell maturation antigen (BCMA)-directed therapies that patients with multiple myeloma may experience. The impact of these barriers on health outcomes is discussed, along with strategies and policy solutions to help overcome them.

This CME activity explores the latest clinical data and provides guidance on when to consider treatment with available B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T-cell therapy, or antibody-drug conjugate (ADC) therapy for patients with relapsed/refractory multiple myeloma (RRMM) based on patient-, disease-, and treatment-related factors.

In this MedX activity, Michael Blaha, MD, explores the evolving landscape of low-density lipoprotein cholesterol (LDL-C) management in patients with atherosclerotic cardiovascular disease (ASCVD), with a focus on the current role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how emerging novel PCSK9 inhibitor formulations may be integrated into clinical practice as they become available.

Evaluate the benefits of newly available anti-VEGF treatment options for DR and DME that may improve visual outcomes.
Discuss effects of delayed and interrupted treatment for DME.

Discuss consequences of delayed or inter­rupted treatment for nAMD
Describe efficacy and safety of newer anti-VEGF treatments for nAMD
Jointly provided by Partners for Advancing Clinical Education and DKBmed, LLC

This activity is supported by educational grants from Genetech and Regeneron Pharmaceuticals Inc.
Discuss consequences of delayed or inter­rupted treatment for nAMD
Describe efficacy and safety of newer anti-VEGF treatments for nAMD

In this online, self-learning activity:

Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in older adults and a major driver of vision-related disability in high-income settings. In the United States, an estimated 18.3 million individuals have non–vision-threatening AMD and approximately 1.5 million have vision-threatening disease, creating substantial direct and indirect economic costs for patients, caregivers, and health systems. Late-stage AMD is commonly categorized as geographic atrophy (GA) or neovascular (or “wet”) AMD (nAMD); nAMD is characterized by macular neovascularization with exudation and/or hemorrhage that can rapidly compromise central vision if not controlled. Without timely therapy, vision decline after conversion to late-stage AMD may be clinically meaningful over weeks to months, and missed opportunities for early suppression can translate into avoidable functional loss.

In this online, self-learning activity:

Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular junction disorder marked by fluctuating, fatigable weakness that can involve ocular, bulbar, limb, and respiratory muscles. In a U.S. claims-based analysis, diagnosed prevalence in 2021 was 37.0 per 100,000 and incidence was 3.1 per 100,000, underscoring a clinically meaningful population at risk for disability and episodic deterioration. Reviews describe persistent symptom burden and functional consequences that extend beyond clinic-based strength testing. Real-world observational data link higher disease severity to greater impairment in activities of daily living, including reduced independence with self-care and mobility. International consensus guidance recommends stepwise management with early steroid-sparing intent and timely adjustment when treatment targets are not met. Higher severity is also associated with worse work productivity and activity impairment, amplifying socioeconomic burden.